Physician profile
Richard E Gordon
NPI 1154313609
$17,100.60
in general payments reported to CMS, 2019-2025
59 companies · $2,782 in 2025
The $2,782 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,074 · 2020: $2,255 · 2021: $2,612 · 2022: $2,358 · 2023: $2,522 · 2024: $2,497 · 2025: $2,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,649 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,649.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,364.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,355.75 | 2019-2025 | |
| Lilly USA, LLC | $1,310.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,187.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $940.57 | 2019-2022 | |
| Pfizer INC. | $933.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $889.38 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Antares Pharma, INC. | $786.01 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $681.06 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.97 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Glaxosmithkline, LLC. | $531.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $525.02 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $481.19 | 2022-2025 | |
| Amgen INC. | $472.01 | 2019-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $373.33 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.